Presentation is loading. Please wait.

Presentation is loading. Please wait.

Outcome Relative risk with beta blockers 95% CI Stroke 1.16 1.04–1.30

Published byἈλκμήνη Λαγός Modified over 5 years ago

Similar presentations

Presentation on theme: "Outcome Relative risk with beta blockers 95% CI Stroke 1.16 1.04–1.30"— Presentation transcript:

1 Meta-analysis of trials comparing beta blockers with other antihypertensives
Outcome Relative risk with beta blockers 95% CI Stroke 1.16 1.04–1.30 MI 1.02 0.93–1.12 All-cause mortality 1.03 0.99–1.08 Lindholm LH, et al. Lancet 2005; available at:

2 Atenolol vs other antihypertensives
Outcome Relative risk with atenolol 95% CI Stroke 1.26 1.15–1.38 MI 1.05 0.91–1.21 All-cause mortality 1.08 1.02–1.14 Lindholm LH, et al. Lancet 2005; available at:

3 Nonatenolol beta blockers vs other antihypertensives
Outcome Relative risk with beta blockers 95% CI Stroke 1.20 0.30–4.71 MI 0.86 0.67–1.11 All-cause mortality 0.89 0.70–1.12 Lindholm LH, et al. Lancet 2005; available at:

4 Combination of beta blockers plus diuretics vs other antihypertensives
Outcome Relative risk with beta blockers 95% CI Stroke 1.09 0.98–1.21 MI 1.00 0.81–1.22 All-cause mortality 0.97 0.89–1.05 Lindholm LH, et al. Lancet 2005; available at:

Download ppt "Outcome Relative risk with beta blockers 95% CI Stroke 1.16 1.04–1.30"

Similar presentations

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.
11/2/2005 1 Implications of ASCOT Results for ALLHAT Conclusions ALLHAT.

11/2/ Implications of ASCOT Results for ALLHAT Conclusions ALLHAT.
Rimoldi SF et al. J Clin Hypertens (Greenwich). 2015;17(3):193-199. Efficacy and safety of calcium channel blocker/diuretics combination therapy in hypertensive.

Rimoldi SF et al. J Clin Hypertens (Greenwich). 2015;17(3): Efficacy and safety of calcium channel blocker/diuretics combination therapy in hypertensive.
Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.

Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.

CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
Is It the Achieved Blood Pressure or Specific Medications that Make a Difference in Outcome, or Is the Question Moot? William C. Cushman, MD Professor,

Is It the Achieved Blood Pressure or Specific Medications that Make a Difference in Outcome, or Is the Question Moot? William C. Cushman, MD Professor,
Systolic hypertension not an isolated problem Michael Weber, MD Professor of Medicine Associate Dean Downstate College of Medicine State University of.

Systolic hypertension not an isolated problem Michael Weber, MD Professor of Medicine Associate Dean Downstate College of Medicine State University of.
1 Antihypertensive Trial Outcome Differences: Diuretic vs. Calcium Channel Blocker Compared to participants assigned to the diuretic, those assigned to.

1 Antihypertensive Trial Outcome Differences: Diuretic vs. Calcium Channel Blocker Compared to participants assigned to the diuretic, those assigned to.
Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:

Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:
Lancet 373:1765-72, 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.
The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.

The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.
ELITE - II Study Design  60 yrs; NYHA II - IV; EF  40 % ACEI naive or  7 days in 3 months prior to entry Standard Rx ( ± Dig / Diuretics ), ß - blocker.

ELITE - II Study Design  60 yrs; NYHA II - IV; EF  40 % ACEI naive or  7 days in 3 months prior to entry Standard Rx ( ± Dig / Diuretics ), ß - blocker.
Guidelines recommend, as first-line treatment for hypertension, a diuretic or the combination of diuretic ± ACE inhibitor. Prevention of Stroke in Patients.

Guidelines recommend, as first-line treatment for hypertension, a diuretic or the combination of diuretic ± ACE inhibitor. Prevention of Stroke in Patients.
Flow Diagram of Identification of Randomized Trials for Inclusion Goran Bjelakovic, et al. JAMA. 2007;297:842-857.

Flow Diagram of Identification of Randomized Trials for Inclusion Goran Bjelakovic, et al. JAMA. 2007;297:
Results from ASCOT-BPLA: Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm VBWG.

Results from ASCOT-BPLA: Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm VBWG.
(p for noninferiority = 0.01)

(p for noninferiority = 0.01)
Blood Pressure and Lipid Trials: Rationale, Importance and Design

Blood Pressure and Lipid Trials: Rationale, Importance and Design
Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals

Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals
LEADER trial: Primary Outcome

LEADER trial: Primary Outcome

Similar presentations

Ads by Google